Group 1 - The core viewpoint of the news is that the Hong Kong pharmaceutical sector is experiencing a rebound, particularly in innovative drug stocks, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising over 3% after a period of decline [1][4] - The Hong Kong Stock Connect Innovative Drug ETF (520880) recorded five consecutive days of decline, reaching a historical low, but saw a capital inflow of over 135 million yuan during this period [1][2] - The healthcare sector in Hong Kong is showing signs of recovery, with major stocks like WuXi Biologics and BeiGene contributing to the rise of the Hong Kong Stock Connect Healthcare ETF [4][6] Group 2 - The total amount of business development (BD) for innovative drugs in China exceeded 50 billion USD in the first two months of 2026, with upfront payments surpassing 3 billion USD, indicating a strong growth trajectory [3] - Chinese pharmaceutical companies are entering a commercialization phase, with companies like Rongchang Bio turning a profit of 709 million yuan in 2025, and BeiGene achieving its first non-GAAP net profit [3] - China National Pharmaceutical Group's stock surged over 5% following the announcement of an exclusive licensing agreement with Sanofi, which includes an upfront payment of 135 million USD and potential milestone payments of up to 1.395 billion USD [1][3]

3月5日早盘，港股医药终于反弹！创新药龙头普涨，100%创新药研发标的——港股通创新药ETF （520880）高开高走，现涨超3%。昨日，520880录得五连跌，场内价格创下历史新低，不过资金逆行 增仓，连续5日低吸合计逾1.35亿元。 投创新药，认准港股通创新药ETF（520880）及其场外联接基金（025221），100%布局创新药研发类 公司，前十大权重股占比超七成，龙头属性突出。 注： ETF 基金不收取销售服务费。投资者在申购或赎回基金份额时，申购赎回代理券商可按照不超过 0.5% 的标准收取佣金，其中包含证券交易所、登记机构等收取的相关费用。基金费率详见各基金法律 文件。 | 分时 多日 1分 · | | | | | F9 盘前盘后 露加 九粒 酒线 工具 (8 (7) > | | | | | | 港股通创新药ETF ① | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 0.468 | | | 520880[用胶通创新的ETF] 10:06 价 0.468 新跌 ...

创新药龙头重磅业绩利好！百济神州2月26日发布2025年度业绩快报，全年营收382.05亿元，同比增 40.4%；归母净利润14.22亿元，实现扭亏为盈。 值得一提的是，这是这家创新药龙头公司首次实现年度盈利，也是中国创新药企全球化发展的重要里程 碑。 公告显示，百济神州业绩增长得益于核心产品放量，2025年百悦泽全球销售额280.67亿元，同比增长 48.8%。此外，公司多款候选药物进入临床关键阶段，百悦达在中国获批上市，BGB-B2033获FDA快速 通道资格认定。 开源证券指出，中国创新药正经历从"规模积累"走向"价值释放"的国际化跨越，并持续迎来从"管线预 期"转向"业绩兑现"的商业化收获期。创新药板块已回调两个季度，长期看，较多优质标的估值性价比 明显，当前位置建议加大关注。* 低位埋伏创新药机遇，借道ETF效率更高！ 投纯正创新药，认准T+0利器——港股通创新药ETF（520880）及其场外联接基金（025221），100%布 局创新药研发类公司，前十大权重股占比超七成，龙头属性突出。 降低波动 | 项目 | 本报告期 | 上年同期 | 增减变动幅度(%) | | --- | --- | --- ...

2月26日午后，港股医药股加速走低，创新药产业链跌幅靠前，港股通创新药ETF（520880） 、港股通 医疗ETF华宝（159137）双双跌逾2%，场内溢价同步走高，显示"抄底"资金有所行动。 个股方面，权重龙头百济神州跌逾6%居首，据悉，该公司将于今日披露2025年财报。作为创新药领域 龙头企业，百济神州为港股通创新药ETF（520880） 、港股通医疗ETF华宝（159137）持仓股，权重占 比分别为11.27%、2.13%。 开源证券指出，中国创新药正经历从"规模积累"走向"价值释放"的国际化跨越，并持续迎来从"管线预 期"转向"业绩兑现"的商业化收获期。创新药板块已回调两个季度，长期看，较多优质标的估值性价比 明显，当前位置建议加大关注。* 低位埋伏港股医药机遇，借道ETF效率更高，高弹性，T+0！ 投创新药，认准港股通创新药ETF（520880）及其场外联接基金（025221），100%布局创新药研发类 公司，前十大权重股占比超七成，龙头属性突出。 投医疗，选港股通医疗ETF华宝（159137），锚定医疗创新，囊括脑机接口、AI医疗、互联网药店等热 点概念，同时覆盖创新药全产业链龙头。 数据来源：中 ...

华创证券指出，创新药行业看好国内从数量逻辑向质量逻辑转换，迎来产品为王的阶段。2025年，建议 更加重视国内差异化和海外国际化的管线，看好最终能够兑现利润的产品和公司。 港股通创新药ETF（520880）被动跟踪恒生港股通创新药精选指数，该指数前十大权重股分别为石药集 团、百济神州、康方生物、中国生物制药、信达生物、翰森制药、三生制药、科伦博泰生物-B、康哲药 业、荣昌生物。 数据来源于沪深交易所、公开资料等。 风险提示：以上产品由基金管理人发行与管理，代销机构不承担产品的投资、兑付和风险管理责任。投 资人应当认真阅读《基金合同》、《招募说明书》、《基金产品资料概要》等基金法律文件，了解基金 的风险收益特征，选择与自身风险承受能力相适应的产品。基金过往业绩并不预示其未来表现，基金投 资须谨慎！销售机构（包括基金管理人直销机构和其他销售机构）根据相关法律法规对本基金进行风险 评价，投资者应及时关注基金管理人出具的适当性意见，各销售机构关于适当性的意见不必然一致，且 基金销售机构所出具的基金产品风险等级评价结果不得低于基金管理人作出的风险等级评价结果。基金 合同中关于基金风险收益特征与基金风险等级因考虑因素不同而 ...

Group 1 - The Hong Kong innovative drug sector experienced a downward trend, with the Hong Kong Stock Connect Innovative Drug ETF (520880) dropping over 1% in early trading on February 26 [1] - Among the constituent stocks, Jiage Ankang-B led with a gain of over 5%, while Baiji Shenzhou fell sharply by 3% [1] - The industry is seeing active external licensing transactions, with Innovent Biologics and Eli Lilly forming a global strategic partnership focused on oncology and immunology [3] Group 2 - Key pipelines are making progress overseas, with two innovative drugs from CSPC Pharmaceutical Group starting Phase III clinical trials and receiving FDA IND approval [3] - Jianghai Securities predicts that by 2026, pharmaceutical business development (BD) transactions will focus on unmet clinical needs, technological differentiation, and globalization [3] - Huachuang Securities emphasizes the transition in the innovative drug industry from quantity to quality, suggesting a focus on differentiated domestic and international pipelines by 2025 [3] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, with top ten weighted stocks including CSPC Pharmaceutical Group and Baiji Shenzhou [3]

Group 1 - The Hong Kong stock market for innovative drugs experienced a decline, with the Hong Kong Stock Connect Innovative Drug ETF (520880) dropping by 2%, and major stocks like CSPC Pharmaceutical, China Biologic Products, and Hansoh Pharmaceutical falling over 2% [1] - The market is expected to see a traditional surge during the Chinese New Year holiday, with an average increase of 2% since 2021 [1] - CICC highlights four key sectors in the A-share market: dividends, internet, innovative drugs, and new consumption, which are considered to have long-term investment value [1] Group 2 - Chinese innovative drugs continue to gain traction internationally, with significant business development (BD) deals, including a partnership between Innovent Biologics and Eli Lilly worth up to $8.85 billion [2] - In January, CSPC Pharmaceutical announced a partnership with AstraZeneca valued at up to $18.5 billion, showcasing the global competitiveness of Chinese innovative drugs [2] Group 3 - The Chinese innovative drug sector is entering a commercialization phase, with over 70% of innovative drug companies reporting revenue growth, and companies like BeiGene achieving revenues exceeding 36 billion yuan [3] - Leading companies are starting to achieve profitability, with firms like Innovent Biologics and Rongchang Biologics reaching annual breakeven, and Elysium achieving over 2 billion yuan in net profit [3] - Open Source Securities expresses optimism about the innovative drug sector and its supply chain, as well as emerging industries like AI and biomanufacturing [3] Group 4 - The Hong Kong pharmaceutical sector has adjusted for nearly two quarters, presenting an attractive investment opportunity, particularly through ETFs for efficient capital allocation [3] - The Hong Kong Stock Connect Innovative Drug ETF (520880) focuses on innovative drug R&D companies, with the top ten holdings accounting for over 73% of the portfolio [3]

2月11日，港股医药有所分化。创新药大面积回调，创新药纯度100%的港股通创新药ETF（520880）微 跌0.19%止步三连阳。医疗主题板块继续上行，港股通医疗ETF华宝（159137）走出四连涨，站上20日 均线。 | 分时 多日 1分 5分 15分 30分 · 给会屏 F9 后复农 超级盘加 面试 工具 @ (1) > | | 港般通医疗ETF华宝 | | 159137 | | --- | --- | --- | --- | --- | | 159137.SZ[桃投通四疗ETF华宜] 2026/02/11 歌 1.024 幅0.49%(0.005) 开 1.025 高 1.030 低 1.019 均回 | | | | | | MAS 1.0021 MA10 0.998 MA20 1.022 2026/01/12-2026/02/11(23日)▼ | | 0 | | +0.005 +0.499 | | | 1,160 | SZSE CNY 15:00:00 闭槽 | | T+0 / 0 | | 4-1,152 | | 净值走势 | | 华宝中证港股通医疗主题ETF | | | | DEF | -51.86 ...

Market Overview - A-shares experienced narrow fluctuations, with the Sci-Tech Innovation Board showing strong performance, particularly in AI applications and computing chips [1] - The Hong Kong stock market saw a significant rebound in the pharmaceutical sector, with the Hong Kong Innovation Drug ETF (520880) reaching a peak increase of 3.86% and closing up 2.9% [3][5] ETF Performance - The Hong Kong Innovation Drug ETF (520880) recorded a trading volume of 5.9 billion, while the Hong Kong Medical ETF (159137) rose by 2.1%, marking its sixth consecutive day of gains [2][3] - The Sci-Tech Artificial Intelligence ETF (589520) increased by 1.81%, with a peak rise of over 2.4% during the trading session [8] Industry Insights - The Chinese innovative drug sector is experiencing a dual breakthrough in internationalization and commercialization, with over 70% of innovative drug companies reporting positive revenue growth [6][7] - Significant collaborations in the innovative drug space include a strategic partnership between Innovent Biologics and Eli Lilly, valued at up to $8.85 billion, and a $18.5 billion collaboration between CSPC Pharmaceutical and AstraZeneca [6] AI and Technology Developments - ByteDance's recent launches, including the Seedance 2.0 video generation model and Seedream 5.0 image generation model, have generated significant interest in the AI sector [11] - The Sci-Tech Artificial Intelligence ETF (589520) has a substantial exposure to ByteDance, with a weight of 29.42% in its index [11][13] Semiconductor and Chip Industry - The semiconductor equipment industry is experiencing an upward trend, with projected sales growth of 26% in 2026, reaching $791.7 billion [17] - The Sci-Tech Chip ETF (589190) is positioned to benefit from the ongoing "super cycle" in the semiconductor industry, with a focus on domestic production and expansion [15][17] Investment Strategy - Analysts suggest that the current market conditions present a favorable opportunity for investment in innovative drugs and AI sectors, with a recommendation to focus on ETFs that track these industries [7][19] - The Sci-Tech Chip ETF has shown a strong annualized return of 17.93%, outperforming other semiconductor indices [19][20]

Group 1 - The core viewpoint is that the Hong Kong pharmaceutical sector is experiencing a strong resurgence, driven by the innovative drug industry chain, particularly led by Innovent Biologics [1][8] - The Hong Kong Stock Connect Innovative Drug ETF (520880) reached a peak of 3.86% and closed up 2.9%, recovering the 20-day moving average with a trading volume of 590 million yuan [1][8] - The Hong Kong Stock Connect Medical ETF (159137), which has a high CXO content, rose by 2.1%, marking its sixth consecutive day of gains [1][8] Group 2 - The Chinese innovative drug sector is witnessing a robust international expansion, with significant business development (BD) transactions occurring [4][10] - Notable collaborations include Innovent Biologics' announcement of a global strategic partnership with Eli Lilly worth up to $8.85 billion, including an upfront payment of $350 million [4][10] - In January, CSPC Pharmaceutical Group entered a platform-level collaboration with AstraZeneca valued at up to $18.5 billion, while Rongchang Biologics secured a $5.6 billion licensing deal with AbbVie, showcasing the global competitiveness of Chinese innovative drugs [4][10] Group 3 - The Chinese innovative drug industry is entering a commercialization phase, with over 70% of innovative drug companies achieving positive revenue growth by 2025 [5][11] - BeiGene reported revenue exceeding 36 billion yuan, demonstrating strong commercialization capabilities [5][11] - Leading companies like Innovent Biologics and Rongchang Biologics have achieved annual breakeven, while Elysium has reported over 2 billion yuan in net profit attributable to shareholders, indicating a transition from R&D investment to performance realization [5][11] Group 4 - Open Source Securities expresses a positive outlook on the innovative drug sector and its supply chain (CXO + research services), as well as emerging national strategic industries such as AI, brain-computer interfaces, and biomanufacturing [5][11] - The Hong Kong pharmaceutical sector has adjusted for nearly two quarters, presenting an attractive investment opportunity [5][11] - Investors are encouraged to consider the Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds, which focus on innovative drug research companies, with the top ten weighted stocks accounting for over 73% [5][11]